<code id='546D09FD60'></code><style id='546D09FD60'></style>
    • <acronym id='546D09FD60'></acronym>
      <center id='546D09FD60'><center id='546D09FD60'><tfoot id='546D09FD60'></tfoot></center><abbr id='546D09FD60'><dir id='546D09FD60'><tfoot id='546D09FD60'></tfoot><noframes id='546D09FD60'>

    • <optgroup id='546D09FD60'><strike id='546D09FD60'><sup id='546D09FD60'></sup></strike><code id='546D09FD60'></code></optgroup>
        1. <b id='546D09FD60'><label id='546D09FD60'><select id='546D09FD60'><dt id='546D09FD60'><span id='546D09FD60'></span></dt></select></label></b><u id='546D09FD60'></u>
          <i id='546D09FD60'><strike id='546D09FD60'><tt id='546D09FD60'><pre id='546D09FD60'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:56
          Illustration of a person walking across a tightrope, trying to balance.
          Adobe

          Hospitals are telling government officials it would be illegal to claw back $7.8 billion as part of a remedy that is making hospitals whole over underpaid drug discounts — and they may sue if that plan goes into effect.

          The industry is walking a tightrope by trying to maximize the amount of money hospitals can keep. Lobbyists are praising federal officials for agreeing to dole out billions of dollars in future, lump-sum payments, but they are also pressuring Medicare not to offset a penny of those funds.

          advertisement

          For several years during the Trump administration, Medicare cut payments for hospitals’ drugs under the federal 340B drug discount program, but the Supreme Court invalidated that policy in 2018. In July, Medicare proposed a solution: Hospitals would get $9 billion to cover what they are owed under the 340B program, but to offset those costs, the government would recoup $7.8 billion.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Teladoc has a new CEO, but challenges remain the same
          Teladoc has a new CEO, but challenges remain the same

          AdobeVirtualcarecompanyTeladochasanewchiefexecutiveofficerfollowingtheabruptdepartureofitslongtimele

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          Sen. Paul opposes bill to ban Chinese biotechs

          Sen.RandPaul(R-Ky.)WinMcNamee/GettyImagesWASHINGTON—ASenatepanelWednesdaypassedabillaimedatpreventin